Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2000 March; 82(6): 1223–1232.
Published online 2000 February 21. doi:  10.1054/bjoc.1999.1067
PMCID: PMC2363350

Sigma-2 receptors as a biomarker of proliferation in solid tumours


Over the past several years, our group has provided considerable evidence that the expression of sigma-2 (σ2) receptors may serve as a biomarker of tumour cell proliferation. In these in vitro studies, σ2receptors were expressed 8–10 times more in proliferative (P) tumour cells than in quiescent (Q) tumour cells, and the extent and kinetics of their expression were independent of a number of biological, physiological and environmental factors often found in solid tumours. Moreover, the expression of σ2receptors followed both the population growth kinetics when Q-cells were recruited into the P-cell compartment and the proliferative status of human breast tumour cells treated with cytostatic concentrations of tamoxifen. However, these in vitro studies may or may not be indicative of what might occur in solid tumours. In the present study, the σ2receptor P:Q ratio was determined for the cells from subcutaneous 66 (diploid) and 67 (aneuploid) tumours grown in female nude mice. The σ2receptor P:Q ratio of the 66 tumours was 10.6 compared to the σ2receptor P:Q ratio of 9.5 measured for the 66 tissue culture model. The σ2receptor P:Q ratio of the 67 tumours was 4.5 compared to the σ2receptor P:Q ratio of ≈ 8 measured for the 67 tissue culture model. The agreement between the solid tumour and tissue culture data indicates that: (1) the expression of σ2receptors may be a reliable biomarker of the proliferative status of solid tumours and (2) radioligands with both high affinity and high selectivity for σ2receptors may have the potential to non-invasively assess the proliferative status of human solid tumours using imaging techniques such as positron emission tomography or single-photon emission computerized tomography. © 2000 Cancer Research Campaign

Keywords: Sigma-2 receptors, biomarkers, proliferative tumour cells, quiescent tumour cells, functional imaging, solid tumours

Full Text

The Full Text of this article is available as a PDF (213K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Al-Nabulsi I, Mach RH, Wang LM, Wallen CA, Keng PC, Sten K, Childers SR, Wheeler KT. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer. 1999 Nov;81(6):925–933. [PMC free article] [PubMed]
  • Amano S, Inoue T, Tomiyoshi K, Ando T, Endo K. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998 Aug;39(8):1424–1427. [PubMed]
  • Begg AC. The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1539–1541. [PubMed]
  • Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, Coscia CJ. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991 Dec 15;51(24):6558–6562. [PubMed]
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. [PubMed]
  • Corvò R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M, et al. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol. 1995 Aug;13(8):1843–1850. [PubMed]
  • Dong H, Bertler C, Schneider E, Ritter MA. Assessment of cell proliferation by AgNOR scores and Ki-67 labeling indices and a comparison with potential doubling times. Cytometry. 1997 Aug 1;28(4):280–288. [PubMed]
  • Dressler LG. DNA flow cytometry measurements and their clinical relevance in node-negative breast cancer patients. Recent Results Cancer Res. 1993;127:61–69. [PubMed]
  • Ehmann UK, Wheeler KT. Cinemicrographic determination of cell progression and division abnormalities after treatment with 1, 3 bis(2-chloroethyl)-l-nitrosourea. Eur J Cancer. 1979 Apr;15(4):461–473. [PubMed]
  • Ehmann UK, Nagasawa H, Petersen DF, Lett JT. Symptoms of X-ray damage to radiosensitive mouse leukemic cells: asynchronous populations. Radiat Res. 1974 Dec;60(3):453–472. [PubMed]
  • Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988 May;14(5):831–838. [PubMed]
  • Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, Oberdorfer F, Rudat V, van Kaick G. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med. 1991 Aug;32(8):1548–1555. [PubMed]
  • Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8072–8077. [PubMed]
  • Haustermans K, Hofland I, Pottie G, Ramaekers M, Begg AC. Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry. 1995 Feb 1;19(2):154–163. [PubMed]
  • Hayes DF. Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res. 1996;140:101–113. [PubMed]
  • Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry. 1993;14(5):482–485. [PubMed]
  • Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994 Jun 15;268(1):9–18. [PubMed]
  • Höckel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 1991 Nov 15;51(22):6098–6102. [PubMed]
  • Kaufmann M. Review of known prognostic variables. Recent Results Cancer Res. 1996;140:77–87. [PubMed]
  • Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun. 1996 Dec 13;229(2):553–558. [PubMed]
  • Leskinen-Kallio S, Någren K, Lehikoinen P, Ruotsalainen U, Joensuu H. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer. 1991 Dec;64(6):1121–1124. [PMC free article] [PubMed]
  • Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med. 1992 May;33(5):724–734. [PubMed]
  • Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997 Jan 1;57(1):156–161. [PubMed]
  • Martiat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, Michaux JL, Sokal G. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med. 1988 Oct;29(10):1633–1637. [PubMed]
  • Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15(2):61–66. [PubMed]
  • Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988 May 1;61(9):1776–1781. [PubMed]
  • Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med. 1993 Nov;34(11):1886–1891. [PubMed]
  • Moebius FF, Striessnig J, Glossmann H. The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol Sci. 1997 Mar;18(3):67–70. [PubMed]
  • Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992 Mar;33(3):325–329. [PubMed]
  • Schabel FM., Jr The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. Cancer Res. 1969 Dec;29(12):2384–2389. [PubMed]
  • Seth P, Leibach FH, Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun. 1997 Dec 18;241(2):535–540. [PubMed]
  • Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V. Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem. 1998 Mar;70(3):922–931. [PubMed]
  • Siemann DW, Lord EM, Keng PC, Wheeler KT. Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation. Br J Cancer. 1981 Jul;44(1):100–108. [PMC free article] [PubMed]
  • Takeda N, Diksic M, Yamamoto YL. The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. Cancer. 1996 Mar 15;77(6):1167–1179. [PubMed]
  • Thames HD, Jr, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983 Feb;9(2):127–138. [PubMed]
  • Tsang RW, Fyles AW, Kirkbride P, Levin W, Manchul LA, Milosevic MF, Rawlings GA, Banerjee D, Pintilie M, Wilson GD. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1319–1329. [PubMed]
  • Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995 Jan 15;55(2):408–413. [PubMed]
  • Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev. 1990 Dec;42(4):355–402. [PubMed]
  • Wallen CA, Higashikubo R, Dethlefsen LA. Murine mammary tumour cells in vitro. I. The development of a quiescent state. Cell Tissue Kinet. 1984 Jan;17(1):65–77. [PubMed]
  • Wallen CA, Higashikubo R, Dethlefsen LA. Murine mammary tumour cells in vitro. II. Recruitment of quiescent cells. Cell Tissue Kinet. 1984 Jan;17(1):79–89. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK